HCA

HCA Healthcare, Inc. (HCA) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This summary covers the unaudited quarterly report (Form 10-Q) for HCA Healthcare, Inc. for the period ended June 30, 2025. HCA is a holding company owning and operating 191 hospitals, 124 freestanding surgery centers, and 29 endoscopy centers across 20 U.S. states and England. The company operates through three geographic groups: National, Atlantic, and American.

Key Financial Metrics

Note: Operating cash flow for Q2 is derived from the six-month total minus Q1 figures or estimated based on MD&A commentary regarding a $2.239 billion increase in Q2 operating cash flow compared to prior year.

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenues increased 6.4% in Q2 2025 compared to Q2 2024, driven by a 3.9% increase in revenue per equivalent admission and a 2.3% increase in equivalent admissions.
• Profitability: Net income attributable to HCA increased 13.1% year-over-year in Q2. The effective tax rate declined to 24.1% from 27.4% due to adjustments in unrecognized tax benefits.
• Volume Trends: Consolidated admissions rose 2.1%. Inpatient surgical volumes increased 0.2%, while outpatient surgical volumes declined 0.2%. Emergency department visits increased 1.0%.
• Cost Structure: Salaries and benefits remained stable at 43.7% of revenue. Supply costs increased to 15.3% of revenue, with medical device costs rising 10.2% per admission due to cardiovascular technologies.
• Debt Refinancing: In February 2025, HCA repaid $2.6 billion in senior notes due at maturity and entered a new $8.0 billion senior unsecured revolving credit facility. The company also issued $5.25 billion in new senior notes with maturities ranging from 2028 to 2055.

Guidance, Outlook, and Risks

• Legislative Impact (OBBBA): The "One Big Beautiful Bill Act" (OBBBA), enacted July 4, 2025, introduces significant healthcare policy changes. It limits Medicaid eligibility via work requirements, restricts provider taxes, and caps State Directed Payments (SDPs). These changes are expected to decrease insurance access and reduce federal spending, particularly in Medicaid.
• Capital Allocation: HCA repurchased $5.011 billion of common stock in the first six months of 2025. A $10 billion share repurchase authorization was approved in January 2025, with $5.753 billion remaining available as of June 30, 2025. A quarterly dividend of $0.72 per share was declared.
• Liquidity: The company reported negative working capital of $376 million at June 30, 2025, primarily due to increased short-term borrowings and accrued expenses. However, excluding commercial paper, working capital would be positive. Management expects cash flows and credit facility availability ($6.2 billion) to meet liquidity needs.
• Risks: Key risks include the impact of the OBBBA on reimbursement rates, potential expiration of enhanced premium tax credits (EPTCs) in 2025, inflationary pressures on labor and supplies, and significant indebtedness ($44.5 billion).

Investor Verification Checklist

• Medicaid Exposure: Verify the specific financial impact of the OBBBA's Medicaid work requirements and SDP caps on the company's Texas and Florida markets, which represent a significant portion of uninsured admissions.
• Debt Service: Confirm the ability to service $44.5 billion in debt with an average interest rate of 5.1% amidst potential refinancing risks in a high-rate environment.
• Uncompensated Care: Monitor the trend in the estimated cost of total uncompensated care, which rose to $1.116 billion in Q2 2025, and its impact on margins.
• Share Repurchases: Assess the sustainability of the aggressive $5 billion+ share buyback program in the first half of 2025 given the negative working capital position.
• Supply Chain Costs: Track the trajectory of medical device costs, which saw a 10.2% increase per admission in Q2, to determine if this is a temporary or structural cost increase.